ATE511653T1 - Annexin zur beurteilung des krebsrisikos - Google Patents

Annexin zur beurteilung des krebsrisikos

Info

Publication number
ATE511653T1
ATE511653T1 AT06743012T AT06743012T ATE511653T1 AT E511653 T1 ATE511653 T1 AT E511653T1 AT 06743012 T AT06743012 T AT 06743012T AT 06743012 T AT06743012 T AT 06743012T AT E511653 T1 ATE511653 T1 AT E511653T1
Authority
AT
Austria
Prior art keywords
annexin
risk assessment
cancer risk
tissue
urogenital
Prior art date
Application number
AT06743012T
Other languages
English (en)
Inventor
Michael Cahill
Andre Schrattenholz
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05011042A external-priority patent/EP1724585A1/de
Application filed by Proteosys Ag filed Critical Proteosys Ag
Application granted granted Critical
Publication of ATE511653T1 publication Critical patent/ATE511653T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06743012T 2005-05-21 2006-05-22 Annexin zur beurteilung des krebsrisikos ATE511653T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011042A EP1724585A1 (de) 2005-05-21 2005-05-21 Annexin für Krebsrisikofeststellung
EP05026092A EP1724586A3 (de) 2005-05-21 2005-11-30 Annexin für Krebsrisikomanagement
PCT/EP2006/004818 WO2006125580A1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment

Publications (1)

Publication Number Publication Date
ATE511653T1 true ATE511653T1 (de) 2011-06-15

Family

ID=36940167

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743012T ATE511653T1 (de) 2005-05-21 2006-05-22 Annexin zur beurteilung des krebsrisikos

Country Status (9)

Country Link
US (1) US8409812B2 (de)
EP (2) EP1724586A3 (de)
JP (1) JP2008545634A (de)
KR (1) KR20080016809A (de)
AT (1) ATE511653T1 (de)
AU (1) AU2006251380B2 (de)
CA (1) CA2608306A1 (de)
PL (1) PL1889067T3 (de)
WO (1) WO2006125580A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2024748B1 (de) * 2006-06-09 2012-12-12 ProteoSys AG Monoklonale anti-annexin-a3-antikörper zum nachweis von prostatakrebs
JP2008202978A (ja) * 2007-02-16 2008-09-04 Hirosaki Univ 前立腺癌の診断方法
CA2682899A1 (en) * 2007-04-12 2008-10-23 Proteosys Ag Autoimmune regulation of prostate cancer by annexin a3
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
AU2008285557B2 (en) 2007-07-19 2014-07-03 Biomerieux Method for the assay of liver fatty acid-binding protein, ACE and CA19-9 for the in vitro diagnosis of colorectal cancer
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
WO2010090264A1 (ja) 2009-02-04 2010-08-12 国立大学法人東京工業大学 Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法
WO2011052244A1 (en) 2009-10-30 2011-05-05 Tokyo Institute Of Technology A method for analyzing PSA, and a method for distinguishing prostate cancer from prostatic hypertrophy using that method for analyzing PSA
FR2968767B1 (fr) 2010-12-08 2012-12-21 Biomerieux Sa Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2013076222A1 (en) 2011-11-23 2013-05-30 Proteosys Ag Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
US9423402B2 (en) * 2011-11-30 2016-08-23 Singapore Health Services Pte. Ltd. GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
FR2991777B1 (fr) 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives
JPWO2016031816A1 (ja) 2014-08-26 2017-06-15 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
CN117018185A (zh) * 2022-03-18 2023-11-10 江苏靶标生物医药研究所有限公司 TNF-α纳米抗体与PGE2联用在制备溃疡性结肠炎药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511829B1 (en) 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
WO2002012280A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
EP1373900A2 (de) * 2001-04-03 2004-01-02 MERCK PATENT GmbH Tumormarker des nierenzellkarcinoms
US6843980B2 (en) 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003058201A2 (en) 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
JP2005532036A (ja) * 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
WO2004079368A2 (en) * 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
CA2555866A1 (en) 2004-02-16 2005-08-25 Proteosys Ag Diagnostic markers for cancer
EP1724585A1 (de) * 2005-05-21 2006-11-22 ProteoSys AG Annexin für Krebsrisikofeststellung
EP2024748B1 (de) * 2006-06-09 2012-12-12 ProteoSys AG Monoklonale anti-annexin-a3-antikörper zum nachweis von prostatakrebs

Also Published As

Publication number Publication date
US8409812B2 (en) 2013-04-02
KR20080016809A (ko) 2008-02-22
CA2608306A1 (en) 2006-11-30
EP1724586A3 (de) 2007-07-04
JP2008545634A (ja) 2008-12-18
PL1889067T3 (pl) 2011-10-31
EP1889067A1 (de) 2008-02-20
AU2006251380A1 (en) 2006-11-30
EP1724586A2 (de) 2006-11-22
WO2006125580A1 (en) 2006-11-30
EP1889067B1 (de) 2011-06-01
HK1118095A1 (en) 2009-01-30
US20100267051A1 (en) 2010-10-21
AU2006251380B2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
PL1889067T3 (pl) Aneksyna do oceny ryzyka wystąpienia raka
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
WO2005114190A3 (en) Methods of identifying biomarkers
EP2517727A3 (de) Biomarker für multiple Sklerose und Verfahren zu ihrer Verwendung
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2011072177A3 (en) Biomarker assay for diagnosis and classification of cardiovascular disease
DE602004027600D1 (de) Genexpressionsmarker für die prognose von brustkrebs
EP2674435A3 (de) Biomarker zur Diagnose von Prostatakrebs und Verfahren dafür
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2008103202A3 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
WO2010028313A3 (en) Phosphoprotein analysis of carcinomas for assessment of drug sensitivity
MX2011006773A (es) Biomarcador.
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
WO2003069553A3 (en) Method of image analysis
EP1993672A4 (de) Na/k-atpase-ligand

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties